XELOX方案治疗晚期胃癌104例

【摘要】 目的探讨奥沙利铂联合卡培他滨(XELOX方案)治疗晚期胃癌的近期疗效和安全性。方法经病理证实的晚期胃癌患者,应用奥沙利铂100～130mg/m2加入5%250ml中静滴2小时;卡培他滨1000mg/m2饭后半小时口服,每日2次,第1～14天;21天为1周期。结果全组患者中CR1例,PR44例,总有效率为43.27%,中位进展时间7.1个月。初治组有效率显著高于复治组(53.57%vs.31.25%,P<0.05),转移灶数目1～2个,比≥3个的治疗有效率高(47.27%vs.13.33%,P<0.05),肝转移及腹膜后淋巴结转移的有效率相对较低。主要不良反应为骨髓抑制、神经毒性、肝功异常,但以I～II度为主。结论 XELOX方案治疗晚期胃癌有效率较高,毒副反应较低,患者耐受性好。更多还原

【Abstract】 Objective To evaluate the response rate ,time to progression ,overall survival , and safety of the combination of oxaliplatin plus capecitabine in treatment of advanced gastric cancer . Methods Previously diagnosed patients with advanced gastric cancer were treated with combination of oxaliplatin (100 130 mg/m2 as a 2h infusion on day 1 ) plus capecitabine (1000 mg/m2/each time , twice daily, days 1～14 ) every 3 weeks . Results All 104 patients were reserved the treatment . One case of complete response (CR) and 44 cases of partial response (PR) were confirmed , giving an overall response rate of 43.27% . The response rate was significantly higher in previously untreated pantients than retreatment pantients 53.57% vs. 31.25%, P <0.05 . The response rate in patients with one or two metastatic lesions was significantly higher than those with more than three lesions 47.27% vs. 13.33% , P <0.05 . The median time to progression was 7.1 months . The main side effects were myelosuppression , gastrointestinal ,toxicity and abnormal hepatic function . Most of above side effects were grade I-II . Conclusion Oxaliplatin plus capecitabine combination chemotherapy is active in patients with advanced gastric cancer .更多还原